Test 2 in clients with very early Parkinson's disease (without L-dopa) was a double‑blind, randomized, placebo-controlled, 6-month test. In this trial, 241 people were registered as well as 116 were randomized to Requip and also 125 to placebo. Individuals were basically just like those in the test described above; concomitant use of selegiline was permitted, but people were not allowed to use anticholinergics or amantadine during the trial. Individuals had a mean condition duration of 2 years as well as limited (not more than a 6-week moment) or no previous direct exposure to L-dopa. The beginning dosage of Requip in this test was 0.25 milligrams three times daily. The dose was titrated at weekly periods by increments of 0.25 milligrams 3 times everyday to a dose of 1 milligrams three times daily. More titrations at regular intervals were at increments of 0.5 milligrams three times daily as much as a dose of 3 mg 3 times daily, and afterwards weekly at increments of 1 milligrams three times daily. Patients were to be titrated to a dose of at the very least 1.5 mg 3 times daily and after that to their maximally allowed dosage, as much as a max of 8 mg 3 times daily. The mean dosage obtained in patients at test endpoint was 15.7 mg/day.

  • Requip